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Abstract
Background: MRSA is a significant contributor to prolonged hospital stay, poor clinical outcome
and increased healthcare costs amongst surgical patients. A PCR test has been developed for rapid
detection of MRSA in nasal swabs. The aims of this study are (1) to estimate the effectiveness of
screening using this rapid PCR tests vs culture in reducing MRSA cross-infection rates; (2) to
compare the cost of each testing strategy, including subsequent health care costs; and (3) to model
different policies for the early identification and control of MRSA infection in surgical patients.
Methods/Design: The study is a prospective two-period cross-over study set in 7 surgical wards
covering different surgical specialities. A total of 10,000 patients > 18 years will be tested over 16
months. The only difference between the two study periods is the method used for the detection
of MRSA in each ward (rapid v conventional culture), with all other infection control practices
remaining consistent between the arms. The study has been designed to complement routine
practice in the NHS. Outcomes are MRSA cross-infection rates (primary outcome) and need for
antibiotic therapy and MRSA-related morbidity. Parallel economic and modelling studies are being
conducted to aid in the interpretation of the results and to evaluate the cost-effectiveness of the
rapid PCR screening strategy.
Discussion: This paper highlights the design, methods and operational aspects of a study evaluating
rapid MRSA screening in the surgical ward setting.
Background
MRSA is a major cause of nosocomial infection in hospi-
tals throughout the world. Rates of infection and coloni-
sation vary substantially between different hospitals both
within and between different countries. The UK has one of
the highest rates within Europe and the need for improved
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intervention has been highlighted by experts in infection
control [1]. In particular, MRSA is a significant contribu-
tor to prolonged hospital stay, poor clinical outcomes and
increased healthcare costs amongst surgical patients [2].
The number of death certificates in England and Wales
mentioning MRSA has increased from 734 in 2001 to
1,629 in 2005, with an increase of 39% from 2004 to
2005 [3]. Despite there being many reports in the litera-
ture of localised successful control of MRSA within the
hospital setting, world-wide the incidence of MRSA con-
tinues to rise outside of areas such as the Netherlands and
Scandinavia, where intensive control has managed to
maintain extremely low rates of MRSA [4].
The major method for instituting control is the microbio-
logical identification of patients either colonised or
infected with MRSA, followed by isolation of these
patients to prevent cross-infection and decolonisation
treatment with topical nasal mupirocin and skin disinfec-
tion to eliminate carriage [5]. The influence of interven-
tions including active screening and isolation policies on
the rates of colonisation and infection caused by MRSA
has been comprehensively reviewed recently [1]. This
review concluded that, most, intervention studies to date
have been poorly designed and poorly controlled, with
only one prospective cross-over cohort study, and two
prospective cohort studies which were less rigorously con-
trolled. In some studies nurse cohorting in bays was prac-
tised on wards and these studies appeared to show a
positive effect [6]. The review also included some compre-
hensive mathematical modelling to try to understand the
variables affecting MRSA colonization rates, and con-
cluded that improvements in detection rates and/or isola-
tion capacity should lead to reduced rates of endemic
MRSA. However, the review group also found inadequate
economic evaluation in all of the studies undertaken,
together with a failure to take adequate account of the
influence of confounding variables. Their recommenda-
tions were that, although current isolation measures
appear to have some effect on maintaining lower levels of
MRSA colonisation in the UK, further research should be
undertaken to provide improved evidence on the clinical
effectiveness and cost-effectiveness of MRSA screening
and isolation interventions.
Staphylococcus aureus strains that express high-level resist-
ance to methicillin (and related agents such as flucloxacil-
lin) produce an additional low affinity penicillin binding
protein (PBP2a) (i.e. not inhibited by beta-lactam antibi-
otics) encoded by the mecA gene. Detection of the mecA
gene in cultures is a reliable surrogate marker for methicil-
lin resistance. Until comparatively recently MRSA detec-
tion has largely relied on conventional culture methods
on agar plates, which can take 48–72 h to obtain a result
[7]. The addition of a broth enrichment step has been
shown to improve the sensitivity, but extends the time to
result to at least 72 h. However, the length of time to
obtain a result limits the usefulness of both these meth-
ods, especially with the increasingly short length of hospi-
tal stays.
In recent years a number of different molecular methods
for the rapid detection of MRSA have been described. The
majority of these rely on multiplexed PCR primers to
detect genes which identify strains as S. aureus (nuc is fre-
quently used) and genes which are involved in the expres-
sion and mediation of methicillin resistance (mecA &fem)
[8,9]. Such methods are generally only applicable to the
identification of purified cultures of staphylococci, and
therefore they cannot be used directly on samples [10].
Furthermore, these assays are unable to provide a reliable
result from nose and other swabs due to the presence of
coagulase negative staphylococci carrying mecA giving rise
to a false positive result if MSSA are also present. Recently
a new rapid test (the IDI-MRSA test) has been developed
which is specific for detecting MRSA in nasal swabs. The
PCR primers amplify the right hand extremity of the SCC-
mec genetic element, which contains the mecA, and orfX,
an opening reading frame, which is specific for S. aureus
[11]. An early evaluation on 288 patients has reported a
91.7% sensitivity with a processing time of 1.5 h [12].
A review commissioned by the NHS Health Technology
Assessment (HTA) Programme has identified a need for
accurate economic assessments of the costs of MRSA con-
trol, including the opportunity costs [13]. A recent Dutch
study has considered cost and shown that implementa-
tion of an aggressive search and destroy MRSA policy
within one large University Medical Centre cost €0.28
million per annum. Although an economic analysis sug-
gests that failure to institute this policy would have
resulted in greater expenditure, this was not based on pro-
spective study data [14]. An extensive survey of the surveil-
lance data reported in Wales supports the assertion that
there are substantial costs associated with MRSA infection,
with a deleterious impact on healthcare outcomes on at
least half of the patients found to be infected [15]. Much
of the attributable cost relates to increased length of stay,
along with treatment with a variety of antibiotics, enteral
feeding, and intensive care [2].
This paper describes the design, methods and operational
aspects of a study investigating the efficacy and cost-effec-
tiveness of rapid MRSA screening and monitoring on sur-
gical wards.
The study has four aims:
1. To measure the impact of screening using rapid MRSA
tests versus the most commonly used current test (i.e. cul-BMC Health Services Research 2007, 7:160 http://www.biomedcentral.com/1472-6963/7/160
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ture plate), both in terms of reduction of MRSA cross-
infection and improved clinical management and health
service resource use.
2. To establish the reliability, turn around time, skills
requirement for IDI test in the diagnosis of MRSA versus
the most commonly used current test.
3. To assess the cost effectiveness of a screening strategy
for MRSA in surgical patients using rapid IDI tests and
infection control strategies versus current national MRSA
control recommendations, and to model the costs and
benefits of different protocols for the early identification
and control of MRSA infection in these patients.
4. To produce generalisable protocols and guidelines, in
the context of laboratory provision and MRSA levels
across the UK, on the use of IDI in the management of
MRSA cross infection in surgical patients.
Methods/Design
Study Setting and Population
The study is set in a large teaching hospital with over
1,200 beds, providing services to a large population with
a wide range of socio-economic, ethnic and age character-
istics. All patients admitted to the 7 surgical wards are
included in the study. The seven wards include general
surgery (2), vascular (1), thoracic (1), ENT (1), trauma
and orthopaedics (2) and urology (1). The total capacity
of the wards ranges between 20 and 34 beds, and in total
is 195 beds; with an average length of stay on the wards of
4.5 days. All of the wards have a limited number of single
rooms (2 – 5), none of which have ensuite facilities.
Inclusion and Exclusion Criteria
All patients aged 18 years plus who have a planned or
emergency admission to a surgical ward, including all
medical patients and internal transfers are included in the
study.
Overall study design and approach
The study is being carried out as a prospective cluster ran-
domised two-period cross over study. A cross over study
design allows a more rigorous means of measuring effec-
tiveness than a simple prospective comparative study
between wards. The only difference between the two study
periods is the method used for the detection of MRSA in
each ward, all other infection control practices are consist-
ent between the wards. The aim of the study is to compare:
(i) 'molecular' wards: patients are screened using the rapid
IDI-MRSA test; and (ii) 'technical' wards: patients are
screened using conventional culture. Results from the
IDI_MRSA test are fed back within 2 hours of receipt of
the samples to the molecular wards and within 2 days to
the technical wards. One study arm contains 4 wards
(Wards A), general surgery (1), trauma and orthopaedic
(1), ENT (1) and thoracics (1), whilst the other arm con-
tains 3 wards (Wards B), general surgery (1), trauma and
orthopaedics (1) and urology (1). In the first period of the
cross-over design, wards A were assigned to the molecular
group and wards B to the technical group, with the assign-
ment reversed for the second period.
Prior to commencement, educational sessions were held
and information leaflets provided to all health care pro-
fessionals working within the surgical directorate to pro-
vide them with information about the study and
emphasise the importance of the work. Patient informa-
tion leaflets, designed to ensure individuals are aware of
necessary procedures for themselves, staff and visitors are
provided.
Ethical approval was received from East Birmingham Eth-
ics Committee. Written consent from study participants is
not required as screening patients for MRSA is hospital
policy. An initial two month pilot period was used to
allow resolution of all operational and technical prob-
lems. This was followed by two 8 month cross-over peri-
ods, with one month follow up of study patients at the
end of the final period. Wards A were allocated to the
molecular arm of the study in the first period and Wards
B to the technical arm.
Sampling
The study design uses only nasal samples for MRSA
screening, for several reasons. Firstly, and most impor-
tantly, at the start of the study all published work evaluat-
ing the IDI-MRSA assay had used only nasal samples [11].
Secondly a nasal sample is easily obtainable for large scale
screening, ensuring comprehensive coverage. Addition-
ally, in previous studies nasal samples have been shown
to have a high sensitivity (84%) [16]. Screening swabs are
taken from all patients on admission and then if the sam-
ple is negative the patient is screened every four days until
discharge, and upon the day of discharge. Regular sam-
pling at 4 daily intervals enables the implementation of
infection control procedures in a timely manner and the
detection of cross infection. Additional samples, for exam-
ple blood cultures and wound swabs are sent on clinical
suspicion as is normal hospital policy.
All samples from the molecular wards are collected by a
research nurse at 8 am and 2 pm, Monday to Friday and
once daily at 1 pm on a Saturday and Sunday. Samples
from the technical wards are transported to the laboratory
using the hospital portering service which operates during
the day 7 days a week.BMC Health Services Research 2007, 7:160 http://www.biomedcentral.com/1472-6963/7/160
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Rapid communication of results to the wards
All results, both positive and negative, are made available
on the laboratory reporting system to which all ward staff
have access via a computerised reporting system, immedi-
ately upon completion of the test. In addition, all positive
MRSA results, both rapid and conventional are tele-
phoned to nurses on the wards, with the time and the per-
son receiving the result documented.
Laboratory protocols
The traditional method for the identification of MRSA is
by culturing swabs directly onto agar plates. A recent
review has concluded that use of Baird-Parker containing
ciprofloxacin agar plate without broth pre-enrichment is
the most cost effective screening strategy [7]. However,
due to the recent emergence of ciprofloxacin sensitive
community MRSA strains, we have chosen not to use this
method [17]. Furthermore, since this publication several
chromogenic agars have been developed which offer a
high degree of sensitivity and specificity [18]. Therefore
the methodology chosen was to use direct inoculation
onto MRSA ID, a chromogenic media, (Biomerieux,
Marcy l'Etoile, France), followed by confirmation using
DNase and slide agglutination tests (Oxoid, Basingstoke,
UK) for identification of Staphylococcus aureus followed by
full sensitivity testing using BSAC methods [19].
The samples from the molecular wards are always received
in batches; on week days two batches of samples are
received, one at 8 am and another at 2 pm, whilst at the
weekend only one batch is processed. On receipt of the
samples all swabs are immediately inoculated directly
onto chromogenic media and then using the same swabs
the DNA is extracted using the BD GeneOhm protocol.
The primers and molecular beacons used are supplied by
the manufacturer (Becton Dickinson, NJ, USA) and the
real time amplification of DNA is run on Smartcyclers™
(Cepheid, CA, USA). All agar plates are read after over-
night incubation, and confirmed using DNase and slide
agglutination followed by full sensitivity testing using
BSAC methods [19].
In cases of discrepant results between the PCR and culture,
all direct culture plates are incubated for an additional 24
h before being reported as negative. Additionally all swabs
which are positive by the PCR method are placed in brain
heart infusion broth (Oxoid, Basingstoke, UK) on the day
the PCR is completed, incubated overnight, sub-cultured
onto chromogenic agar and confirmed as above. This
additional step was added because it is known that
although direct culture is the preferred method of detect-
ing MRSA for operational reasons in the UK i.e. due to cost
and time implications, it is not the most sensitive.
Swabs from the technical wards are processed throughout
the day, Monday to Friday and on Saturday mornings. The
swabs are inoculated directly onto chromogenic agar and
confirmed as previously described. All MRSA isolates,
from both the technical and molecular wards are saved on
protect beads and stored at -80C. The first isolate from
each patient is epidemiologically typed using staphyloco-
ccal interspersed repeat unit (SIRU) typing as previously
described and all results entered into Bionumerics™ [20].
Patient follow up
Prior to starting the study the length of stay on each of the
surgical wards was obtained and was shown to be an aver-
age 4 days. Therefore it is also necessary to capture data
regarding any surgical site infections post discharge. On
discharge from the study ward each patient receives a let-
ter and a questionnaire to be completed by their general
practitioner (GP) in the event that they visit their GP for
treatment of their surgical site wound. The questionnaire
collects follow up information on whether any antibiotics
have been prescribed by the GP and the state of the surgi-
cal site wound. In addition, the consultants who review
the patient in outpatients are asked to complete the same
questionnaire if they identify a surgical site infection.
Patient information and communication
Upon admission to a study ward all patients receive an
information leaflet about the study; detailing what MRSA
is, why it is important to screen for MRSA and why we are
undertaking the study. A research nurse is available to pro-
vide further information and answer questions. If a
patient is found to be MRSA positive during their stay they
are given a second information leaflet answering a
number of questions regarding colonisation with MRSA,
and in addition they receive a third information sheet on
the correct use of the decolonisation treatment. Upon dis-
charge from the ward each patient receives a final infor-
mation sheet as well as a questionnaire to be completed
by their GP following any visit regarding their surgical site.
For short stay patients who are discharged before their
admission result is available, a letter is sent to them at
home informing them that MRSA had been isolated from
a screening sample. This is accompanied by an informa-
tion sheet with contact details for a research nurse they
were able to phone for information and reassurance
regarding the MRSA. If the patient is discharged to a nurs-
ing home the community infection control nurses is con-
tacted and liaises with the nursing home.
Implementation of infection control measures
The infection control procedures implemented are stand-
ardised across all wards regardless of the method of testing
for MRSA. Upon identification of a patient being colo-
nised with MRSA the result is telephoned to the ward. If
space is available, the patient will be placed in a side roomBMC Health Services Research 2007, 7:160 http://www.biomedcentral.com/1472-6963/7/160
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on the ward. If a side room is not available, or if the
patient needs to be observed, the individual will nursed
on the open ward. When operationally possible wards
with several patients colonised with MRSA will nurse
these patients together in one bay (cohort nursing) and
dedicate a specific nurse to care for the patients. For all
these patients an isolation precautions barrier sign (yel-
low and black) is placed by the bed side; gloves, aprons
and alcohol gel are placed at the end of the bed and the
patient is commenced on decolonisation treatment.
Decolonisation treatment consists of five days of aquasept
skin wash, containing triclosan and mupirocin nasal
cream, followed by two days of no treatment and then re-
screening of the patient. For patients who have strains that
are resistant to mupirocin, Polyfax, containing polymyxin
B and bacitracin, is used as the alternative. Additionally all
patients who are colonised with MRSA receive a surgical
review, this is aimed at establishing whether the surgical
procedure is necessary immediately or can be delayed. In
the former case the surgical prophylaxis is changed to
teicoplanin (standard prophylaxis is cefuroxime and met-
ronidazole), but if it is possible to delay surgery the
patient undergoes a course of decolonisation treatment as
detailed above, either at home or within the hospital.
The implementation of all infection control measures is
audited within 12 hours of a patient being identified as
being colonised with MRSA followed by continuous mon-
itoring during their admission by the study research
nurses. All measures are documented, and any failures to
comply with these are both documented and rectified.
Data collection
A comprehensive data set is being collected on all study
patients. Data is entered directly by the research nurses
onto laptops on the wards using a specifically modified
Access database and then uploaded onto a secure server.
Information collected includes patient ID, demographic
data, risk factors, antibiotic usage, bed movements, length
of stay, and treatment outcomes. For patients who are col-
onised with MRSA additional information is collected
regarding implementation of infection control measures
and decolonisation treatment.
Laboratory data collated includes patient ID, date and
time sample taken and received by lab, and the IDI_MRSA
and culture results.
Data analyses
Analysis will be based on all individuals presenting for
admission to the 7 surgical wards (intention to treat),
including emergency and planned admissions. Numerical
and graphical summaries of all the data will be compiled,
including a detailed description of missing data at the
ward and individual level.
Sensitivity and specificity will be estimated for PCR and
culture tests. Receiver operating characteristic (ROC)
curves are not appropriate because this is not a quantita-
tive test. However, the positive predictive value (PPV) and
negative predictive value (NPV) will be calculated. We will
examine test replicability (i.e. precision) which reflects the
variance in a test result that occurs when the test is
repeated on the same specimen. Test reliability (e.g. fail-
ure rates) and laboratory turn-around time will also be
compared.
The main clinical outcome measures will be MRSA cross-
transmission rates, antibiotic therapy and MRSA-related
morbidity. Secondary outcome measures will include
length of in-patient stay, ITU episodes, a final outcome
recorded at discharge, and MRSA infection at the outpa-
tient follow-up clinic. Measures of resource use will
include the cost of hospital episode and any re-admis-
sions for MRSA.
The numbers of patients becoming infected, the cross-
transmission rates and the numbers of MRSA-related
deaths within each ward will be compared for the molec-
ular and technical periods. The main analysis will focus
on ward by period level data summaries. It seems likely
that the number of new MRSA cases observed in each
ward in each period will follow a Poisson distribution
with mean depending on the size and type of the ward
and whether the molecular or technical testing is being
used in that period. A non-linear repeated measures ran-
dom-effects analysis will be used to compare the mean
number of cases, rate of cross-infection and number of
MRSA related deaths. Ward by period interaction-level
covariates could be included in this analysis. Depending
on the observed rate of MRSA colonisation or infection
and admission to the different wards, a normal approxi-
mation to the Poisson distribution may be appropriate,
enabling linear modelling techniques to be used.
Further analyses will use linear or non-linear mixed effect
models to assess the effects patient-level covariates. Esti-
mates of the difference between the molecular and techni-
cal periods adjusted for the effect of covariates will be
obtained.
Health service resource use will similarly be compared.
Sample size
Given the limitations on published data available to
inform the sample size estimate at the outset of the study,
it was decided, in the light of operational constraints, to
monitor MRSA colonisation and infection rates in seven
wards for eighteen months, with a cross-over from molec-
ular to technical testing or vice versa after nine months.
Admission rates to the wards led to an estimated total ofBMC Health Services Research 2007, 7:160 http://www.biomedcentral.com/1472-6963/7/160
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10,000 patients being included in the study, with 5000
being assigned to each of the two periods.
Assuming that 5% of patients are MRSA colonised on
admission to the wards, with a transmission rate in the
technical wards of 0.5, a total of 125 new cases of infec-
tion in the control arm would be expected.
The power of the study can be calculated assuming that
the number of new cases follows a Poisson distribution
and using the normal approximation to the Poisson. If,
for the purpose of the power calculation, it is assumed
that admission rates and MRSA colonisation rates on
admission are the same for all seven wards and in both
periods, and that and MRSA transmission rates are the
same for all wards using molecular or technical testing, a
total of 10,000 admitted patients would mean that the
study had 90% power to detect a reduction in the trans-
mission rate from 0.5 to 0.3, corresponding to a drop in
the expected number of new cases in the molecular wards
from 125 to 75.
Economic analysis
MRSA transmission may have a range of direct cost conse-
quences to healthcare. The costing study will estimate dif-
ferences in the cost of resources used in the molecular and
technical wards. The economic analysis will compare
resource use (costs) with any measurable changes in
health outcomes (benefits). The health outcomes (or end-
points) will be measured in terms of changes in MRSA
transmission and subsequent health outcomes. Any
uncertainties in the cost and outcomes data will be incor-
porated into a sensitivity analysis.
The cost of each test will be determined through observa-
tion in the laboratory, once the learning curve is over and
routine use of the technology is established. Maximum
throughput for each method will be estimated. Test costs
will include: labour (skill levels will be assessed for partic-
ular tasks); consumables; capital (converted into an
annual equivalent cost and apportioned to tests based on
annual throughput); maintenance costs; and overheads.
In both types of ward, other NHS costs related to patient
care will be estimated. These will include resources associ-
ated with length of stay/ITU episodes, prescribing costs,
and for MRSA positives post discharge care costs, includ-
ing subsequent admissions for MRSA. Costs of any other
relevant treatment will also be recorded. The use of serv-
ices will be costed from a variety of sources, including the
finance departments of the hospital and national sources
[21]. Hospital notes and records will also be audited for
information on service use.
The appropriate technique of economic evaluation will
depend on the results of the study [22]. The simplest even-
tuality would be where the least expensive intervention is
found to be better on at least one outcome measure and
no worse on any other i.e. dominant. Another is where
two interventions have the same  outcomes (e.g. MRSA
cross-infection rates), in which case the economic evalua-
tion required when comparing the two is a cost-minimisa-
tion analysis. However, where an intervention is clearly
better in terms of outcome but also more costly, a differ-
ent approach is required. One accepted method is to com-
pare the different interventions in terms of a single
outcome measure identified as clinically important. The
primary outcome measure meets this requirement. There-
fore, the cost per unit improvement in MRSA transmission
rate will be used to provide an estimate of overall cost-
effectiveness of a screening strategy for MRSA in surgical
patients using rapid IDI tests and infection control strate-
gies.
Modelling
Modelling will be undertaken of the policies for early
identification and control of MRSA colonisation and
infection in surgical patients. The purpose of this model-
ling is to understand and describe the transmission of
infection within hospital wards in order to evaluate the
effect of different policies with respect to speed of detec-
tion of infection and the means of prevention of transmis-
sion. We can for example compare the impact of using the
rapid IDI-MRSA test on a theoretical ward with good iso-
lation and cohort facilities as compared to one without.
There have been several previous models of MRSA trans-
mission, including Cooper et al. who criticised previous
models of MRSA transmission because they do not
account for its persistence in hospitals [1,23]. They them-
selves produced compartmental deterministic and sto-
chastic models to describe the transmission of MRSA with
and without patient isolation. These models depict the
movement between community and hospital and assume
that all infection is transmitted directly from patient to
patient, with all uninfected non-isolated patients being
equally likely to be infected. On a detailed micro-level this
is rather simplistic as, in practice, patients who are in close
proximity to patients colonised with MRSA, or are admit-
ted to intensive care are at greater risk of acquiring with
MRSA [24].
Our modelling approach is to use agent based simulation
which is a relatively new technique in this area for which
user friendly software is now available. In agent-based
simulation, each patient or carer can be an agent and can
carry their own parameters for transmission or infection,
which may depend on their location, hygiene levels and
other factors.BMC Health Services Research 2007, 7:160 http://www.biomedcentral.com/1472-6963/7/160
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In order to prime the model with data, we are using the
most recent information from the literature concerning
the mode of transmission of MRSA. Furthermore, as the
modelling exercise is taking place towards the end of the
research project we are able to take advantage of the data
collected in the primary research.
The results from the model will enable us to evaluate dif-
ferent hospital policies to reduce the spread of MRSA.
They will show the effectiveness in terms of a reduced col-
onisation or infection rate and the potential benefits of
rapid testing. Finally we aim to show how powerful, flex-
ible and effective agent based simulation is, in this con-
text.
Discussion
We have described the protocol and initial stages of the
conduct of a large scale UK prospective cross-over study
designed to evaluate the use of a rapid PCR testing for
MRSA screening in patients admitted to 7 surgical wards
in a large teaching hospital. To date, similar intervention
studies have been poorly designed and controlled, with
inadequate economic evaluation [25]. Most of these stud-
ies have been conducted in a single ward, predominantly
ICUs. The main challenges in studying this area include
ensuring that there are no changes to the hospital infra-
structure and that policies and procedures remain
unchanged during the study period, as well as the need to
adequately consider all confounding variables.
The present study will be of importance in establishing
the costs and benefits of introducing rapid MRSA screen-
ing in a standard NHS hospital setting which have limited
single rooms. Also, due to high occupancy rates and
dependency based nursing, cohort nursing in bays for
patients who are colonised or infected with MRSA may
not always be possible, despite best efforts of staff. This
represents the situation in most hospitals in the UK. Dur-
ing the initial setting up of the study rapid transmission of
results direct to a key nurse on the molecular wards using
a text bleep system was envisaged. However, obstacles
were encountered in maintaining confidentiality when
texting patient identifiable information and in staff
responsibility for the bleep. Individual nurses were reluc-
tant to carry the bleep which was therefore often left on
the nurses' workstation and therefore results were not
always acted upon. Instead results were made available on
a computerised laboratory reporting system accessible to
all ward staff and positive MRSA results telephoned
directly to nurses on the ward.
The study is currently completing the recruitment phase
and is running well. Rapid MRSA screening has been well
received by both patients and clinicians, following an ini-
tial reluctance of nursing staff to take on additional tasks.
Much effort has gone into maintaining the profile of the
study across all staff on the surgical wards, in the labora-
tory, and in the hospital infection control team.
The main strengths of the study are its prospective control-
led design, the integral economic evaluation, the use of
mathematical modelling and epidemiological typing to
accurately identify transmission events and to enable the
determination of optimum ways of reducing transmis-
sion, and the general applicability of the final findings to
the current infrastructural context (e.g. isolation capabil-
ity) of the NHS.
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